10-Q: Zeo ScientifiX Reports Widening Losses Amidst Revenue Shifts and Ongoing Going Concern Doubts

Zeo ScientifiX, a clinical-stage biopharmaceutical company, reported an increased net loss for the six months ended April 30, 2025, alongside a significant going concern warning and shifts in product revenue streams.

Summary

• Zeo ScientifiX, Inc. reported a net loss of $2,634,000 for the six months ended April 30, 2025, an increase from $2,439,000 for the same period in 2024.
• Total revenues for the six months ended April 30, 2025, decreased by 2.0% to $2,239,000, down from $2,285,000 in the prior year period.
• Revenue from Higher Concentration Allogenic Aesthetic Biologics significantly decreased by $583,000 (-25.5%) to $875,000, while Lower Concentration Allogenic Aesthetic Biologics saw an increase of $185,000 (8.1%) to $738,000.
• The PPX service platform experienced substantial revenue growth, increasing by $347,000 (15.2%) to $516,000 for the six months ended April 30, 2025.
• Gross profit decreased by 2.7% to $1,792,000, with gross margin slightly down to 80.0% from 80.6%.
• General and administrative expenses decreased by 2.8% to $4,439,000, primarily due to reduced payroll, consulting fees, and commissions.
• Cash used in operating activities significantly improved, decreasing to $78,000 for the six months ended April 30, 2025, compared to $990,000 in the prior year.
• The company's cash balance at April 30, 2025, was $542,000, down from $657,000 at October 31, 2024.
• A stockholders deficit of $2,100,000 was reported as of April 30, 2025, an increase from $1,653,000 at October 31, 2024.
• The company entered into a Binding Memorandum of Understanding with BioXtek, LLC on February 4, 2025, for a joint venture to develop and commercialize membrane products and seek FDA BLA licenses.
• New employment agreements were made for Dr. Peter A. M. Everts as Chief Scientific and Technology Officer and Ron Borsheim as Chief Sales Officer Aesthetics.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to the increased net loss, persistent going concern warning, declining overall revenue, and significant regulatory uncertainty regarding product sales. While there are positives like improved operational cash flow and strategic partnerships, the fundamental financial health and regulatory risks outweigh them, indicating a challenging outlook.

Positives

• Net cash used in operating activities significantly decreased to $78,000 for the six months ended April 30, 2025, a substantial improvement from $990,000 in the prior year period, indicating improved operational cash management.
• General and administrative expenses decreased by $129,000 or 2.8% for the six months ended April 30, 2025, primarily due to reduced payroll, consulting fees, and commissions.
• Revenue from the PPX service platform showed strong growth, increasing by $347,000 or 15.2% for the six months ended April 30, 2025, driven by continued sales and marketing efforts.
• The company launched its first collaborative topical product, ZEO HAIR GROW Powered By Exotropin, in November 2024, expanding into the aesthetic market.
• A joint venture with BioXtek, LLC was established to pursue development and commercialization of membrane products and seek FDA BLA licenses, potentially diversifying product offerings and regulatory pathways.

Negatives

• The net loss increased to $2,634,000 for the six months ended April 30, 2025, compared to $2,439,000 for the same period in 2024, indicating a widening loss.
• Total revenues slightly decreased by 2.0% for the six months ended April 30, 2025, primarily due to a significant decline in higher concentration allogenic aesthetic biologic products.
• The company reported a stockholders deficit of $2,100,000 at April 30, 2025, an increase from $1,653,000 at October 31, 2024, indicating a worsening equity position.
• Cash and cash equivalents decreased to $542,000 at April 30, 2025, from $657,000 at October 31, 2024.
• Other income significantly decreased by $278,000 for the six months ended April 30, 2025, primarily due to non-recurring income from insurance claims and liability settlements in the prior year, and reduced commissions from Exotropin products.
• The company's disclosure controls and procedures were deemed not effective as of April 30, 2025, and material weaknesses in internal control over financial reporting persist.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next 12 months due to limited revenues, recurring net losses, and a stockholders deficit.
• The company's products may be subject to FDA regulations (Section 351 of the Public Health Services Act pertaining to HCT/Ps) requiring an approved biologics license application (BLA), which the company has not obtained, posing a risk to continued sales and distribution in the U.S.
• The company is dependent on additional investment capital to fund ongoing operating expenses and research and development costs, and future funding is anticipated to be costly and dilutive, if available at all.
• The company has been unsuccessful in achieving a stabilized source of revenues since July 2015, and there is no assurance that revenues will increase and stabilize.
• The company faces product competition in the marketplace and uncertainties surrounding the United States economy, which have impacted demand for its higher-priced allogenic aesthetic biologic products.
• A lawsuit has been filed by former Chief Science Officer Howard Golub for $150,000 in alleged unpaid severance, which the company intends to vigorously defend against.
• The company's current market capitalization, common stock liquidity, and available authorized shares may hinder its ability to raise equity proceeds.
• There is no assurance that the company's research and development activities will be successful or that the required costs for these activities can be timely funded.
• The company's disclosure controls and procedures were not effective, and material weaknesses in internal control over financial reporting exist, which could impact financial reporting reliability.

Future Outlook

Management anticipates that the company will remain dependent on additional investment capital to fund ongoing operating expenses and research and development costs, particularly for new product development and required clinical studies. The company is pursuing efforts to complete approved clinical studies and obtain approval for additional studies. It is also undertaking efforts to mitigate potential risks associated with adverse FDA rulings by continuing clinical trials, expanding international sales, and developing new product offerings or designations that may not fall under current regulations. The company expects future funding, if available, to be costly and dilutive.

Management Comments

• "The Company attributes the decrease in revenues from higher and lower concentration allogenic aesthetic biologic products sold during the three months ended April 30, 2025, compared to the three months ended April 30, 2024 due to additional product competition in the marketplace and ongoing uncertainties surrounding the United States economy which attracted greater demand for the Companys lower priced allogenic aesthetic biologic product offerings."
• "The increase in the overall unit sales associated with its PPX service platform was primarily due the Companys continued sales and marketing efforts which included engaging additional sales representatives, participation in industry related conferences, sponsoring of educational webinars and from sales of PPX to the Companys existing customers."
• "The decrease in payroll related expenses during the six months ended April 30, 2025, from the six months ended April 30, 2024, was principally the result of the non-renewal of certain executive employment contracts in May 2024."
• "We do not believe that our products fall within these guidelines and intend to vigorously defend against any adverse interpretation by the FDA on the classification of our products that may be deemed as falling under this defined regulation, if any."
• "Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products."

Industry Context

Zeo ScientifiX operates in the highly regulated and competitive biopharmaceutical and regenerative medicine sectors, with a recent expansion into topical aesthetic applications. The shift in revenue from higher-concentration to lower-concentration aesthetic biologics and increased demand for its PPX service platform suggests a market trend towards more accessible or lower-cost solutions, possibly driven by economic uncertainties and increased competition. The company's efforts to secure FDA BLA licenses and expand internationally reflect the significant regulatory hurdles and global market opportunities in the biologics space. The joint venture with BioXtek for membrane products indicates a strategic move to diversify its product portfolio within the healthcare industry, targeting wound care and surgical markets.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Howard Golub, M.D., the company's former Chief Science Officer, filed a complaint on November 19, 2024, in Broward County, Florida, alleging breach of contract for unpaid severance of $150,000. The company intends to vigorously defend against the lawsuit.
• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business, which are subject to inherent uncertainties and could harm the business.

Related Party Transactions

• Sales of approximately $24,000 for both the three and six months ended April 30, 2025, were made to a management services organization (MSO) in which Dr. George Shapiro, the company's Chief Medical Officer and a board member, has an indirect economic interest.
• The company received a capital call notice from Exotropin LLC (an affiliate in which the company holds an equity interest) for its pro-rata share of $126,000 in November 2024. The company has not yet committed to participating, which would reduce its interest in Exotropin to approximately 5.6% if other members fully participate.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future capital raises, ongoing losses, and a substantial going concern warning. The stock price may be negatively impacted by the declining revenues in key product lines and regulatory uncertainties.
• **Employees**: The company's financial instability and ongoing losses could impact job security and future compensation. New employment agreements for key officers suggest a focus on retaining critical talent despite financial challenges.
• **Customers**: Shifts in product demand towards lower-priced offerings and the company's financial health could affect product availability or support. Regulatory uncertainties regarding FDA compliance could impact the long-term availability of certain products.
• **Creditors**: The company's going concern warning and increasing liabilities pose a risk to creditors, as the ability to meet obligations is uncertain without additional funding or revenue stabilization.
• **Suppliers**: The company's financial condition and potential for restructuring or closure could impact its ability to pay suppliers, potentially leading to disruptions in the supply chain.

Next Steps

• Complete already approved clinical studies for Zofin and PPX and obtain approval to commence additional studies for other specific indications.
• Relocate current operations to sublet space at the BioXtek Facility in Pompano Beach, Florida, expected by May 31, 2025.
• Establish a jointly-owned (50/50) special purpose entity (SPE) with BioXtek, LLC to pursue development and commercialization of membrane patches.
• Conduct and complete required clinical trials and/or studies for mutually agreed upon indications and products within the SPE, with the goal of obtaining FDA BLA license.
• Work in good faith with BioXtek towards the preparation, authorization, execution, and delivery of definitive agreements for the Joint Venture.
• Continue efforts to mitigate potential risks associated with adverse FDA rulings by expanding sales internationally and developing new product offerings and/or designations.
• Vigorously defend against the lawsuit filed by former Chief Science Officer Howard Golub.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Regenerative Medicine, SEC Filing, 10-Q, Zofin, Patient Pure X, PPX, Aesthetic Biologics, FDA Regulation, Going Concern, Clinical Stage, Biotech, Healthcare, Topical Products, Joint Venture, Financial Performance, Stockholders Deficit, Cash Flow, Corporate Governance